Introduction
The CALM-AF10 fusion gene results from in-frame fusions of the CALM gene on chromosome 11 to the AF10 gene on chromosome 10. CALM-AF10 fusions are observed in acute myeloid leukemia (AML), acute lymphoblastic leukemia and malignant lymphoma [1] [2] [3] [4] [5] [6] and are especially prevalent in g-d lineage T-acute lymphoblastic leukemias. 6 AML patients with this translocation have a significantly poorer prognosis as compared with patients without these translocations.
7 AF10 belongs to a family of proteins that includes AF17 and BR140. 8 These proteins harbor a highly conserved plant homeodomain in the N-terminal portion and an octapeptide motif (EQLLERQW) and leucine-zipper (OM-LZ) domain in the C-terminal region. 8, 9 Leukemia-associated translocations consistently fuse the C-terminal OM-LZ domain either to the MLL gene (in the case of MLL-AF10 and MLL-AF17 fusions) or to CALM (in the case of CALM-AF10 fusions). 8, 10, 11 Consistent inclusion of the AF10 and AF17 OM-LZ domains in leukemic fusions highlights the potential importance of these highly conserved motifs in leukemogenesis. Indeed, it has been demonstrated that the interactions of AF10 with critical components of the chromatin modifying machinery are mediated by the OM-LZ domain. [12] [13] [14] Importantly, aberrant recruitment of the histone methyltransferase DOT1L by the OM-LZ domain of AF10 is thought to be critical for the leukemogenesis of MLL-AF10 and CALM-AF10 fusions. 13, 15, 16 Since MLL-AF10 and CALM-AF10-positive leukemias are marked by global hypomethylation of histone H3 lysine 79 (H3K79), as well as HOXA cluster-specific local H3K79 hypermethylation, these diseases could serve as excellent models for studying the contribution of aberrant epigenetic marks to neoplastic development. 17 We have demonstrated that the expression of the human CALM/AF10 fusion gene in murine bone marrow (BM) stem and progenitor cells results in an aggressive AML in vivo. 18 Similar results have also been obtained by expressing this fusion gene under the control of the hematopoietically active Vav promoter in transgenic mice. 19 In a separate study, continuous expression of this fusion gene was shown to be necessary for leukemia propagation, since suppression of CALM/AF10 transcripts by shRNA knockdown significantly increased the latency of leukemia induced by the t(10;11)(p13-14;q14-21) positive U937 human leukemia cell line. 16 Data from patients with CALM-AF10-positive leukemia have demonstrated that despite splicing events, key functional domains of the fusion gene are retained. 20 In this study, we define the leukemogenic activity of key domains of CALM-AF10 by appropriate in vitro and in vivo assays and demonstrate that the leukemogenic activity of CALM-AF10 is due to the function of two regions, the clathrin-binding domain and the OM-LZ domain.
Materials and methods

Generation of CALM-AF10 mutant constructs
The pMIG-CALM-AF10 construct has been described previously. 18 A PCR amplified fragment corresponding to amino acids 1-648 of CALM (NCBI accession NP_009097.2) with a stop codon was cloned into the MSCV-IRES-YFP (pMIY) plasmid vector for generating the CALMD3 0 mutant. For the CALM þ OM-LZ mutant, a PCR amplified fragment corresponding to amino acids 1-648 of CALM was fused to a PCR amplified fragment encoding amino acids 677-758 of AF10 (Accession: NP_001182555), comprising the OM þ LZ with a stop codon. The CALM-AF10 DOM-LZ construct was generated by ligating two separate PCR fragments of CALM-AF10 such that the OM-LZ domain was excluded from between the two fragments, thereby excluding amino acids 677-758 of AF10. Mutants for interrogation of the CALM portion were generated by fusing an EcoR1-BamH1 fragment of either amino acids 1-410 or 400-648 of CALM to the AF10 amino acids 677-758 of AF10 in the MSCV-IRES-GFP vector.
Mice and retroviral infection of BM cells
Parental strain mice were bred and maintained at the Helmholtz Centre Munich animal facility. Donors of primary BM cells were 8-to 12-week-old (C57BL/6Ly-Pep3b Â C3H/HeJ) F 1 (PepC3) mice, and recipients were 8-to 12-week-old (C57BL/6J Â C3H/ HeJ) F 1 (B6C3) mice. Donors were treated with 5-fluorouracil and 5 days later, BM from these mice was harvested and plated in BM medium (Dulbecco's modied Eagle's medium, 15% fetal bovine serum, 1% Pen/Strep) þ cytokines (100 ng/ml stem cell factor, 10 ng/ml interleukin 6 (IL6), 6 ng/ml interleukin 3 (IL3)). After 48 h of pre-stimulation, the BM cells were transduced with different viruses by overlaying them on virus-producing irradiated (40 Gy) GP þ E86 producers in the presence of cytokines and protamine sulfate (5 mg/ml). The transduction was stopped by removing the BM cells from the GP þ E86 cells and plating them in BM medium with cytokines for another 48 h to allow for green fluorescent protein (GFP) expression. Retrovirally transduced cells were sorted based on expression of GFP by using a FACSVantage (Becton Dickinson, Franklin Lakes, NJ, USA). Sorted GFP or yellow fluorescent protein (YFP)-positive cells were used for colony forming cell (CFC) or colony forming unit-spleen (CFU-S) assays or injected directly into recipient mice.
CFU-S assay
The CFU-S assay was performed as previously described. 21 Transduced and sorted 5-fluorouracil-treated BM cells were injected intravenously into lethally irradiated (800 cGy of 137Cs g-radiation) (C57BL/6J Â C3H/HeJ) F 1 (B6C3) mice at cell numbers adjusted to give 5 to 15 macroscopic spleen colonies. Cell doses ranged from 1.5 to 5 Â 10 4 sorted cells. At 12 days after injection, animals were killed and the number of macroscopic colonies on the spleen was evaluated after fixation in Telleyesniczky solution (absolute ethanol, glacial acetic acid and formaldehyde mixed in a 9:1:1 ratio, respectively). For the CALM (400-648) þ AF10 (677-758) mutant, mice were injected with fewer cells to ensure scoring resolution (1000 GFP sorted cells per mouse).
BM transplantation and assessment of mice
In all, 8-to 10-week-old recipient mice (C57BL/6J Â C3H/HeJ) F 1 (B6C3) were irradiated (800 cGy) from a 137 Cs g-radiation source. Fluorescence activated cell sorting-purified transduced BM cells, or a defined ratio of transduced and untransduced cells was injected into the tail vein of irradiated recipient mice. Hematopoietic engraftment of GFP-positive cells was assessed by flow cytometry of regularly collected peripheral blood samples. Mice were closely monitored for signs of disease manifestation and killed when moribund. BM, peripheral blood and spleen cells of killed leukemic or control mice were analyzed for morphology and flow cytometric assessment of lineage markers as described. 18 Gr-1, ScaI, Ter-119, CD4, Mac1, Kit, B220 or CD8 antibodies were used for analysis (all antibodies from BD Biosciences, San Jose, CA, USA). Stained cells were analyzed on a FACSCalibur flow cytometer using the CellQuestPro software (BD Pharmingen, San Diego, CA, USA). Histological analysis and immunohistochemistry was performed on fixed organs of representative leukemic mice using standard protocols.
Colony forming cells
For in vitro CFC assays, transduced cells were sorted for GFP and directly plated in 1% myeloid-conditioned methylcellulose containing Iscove's modified Dulbecco medium-based Methocult (Methocult M3434; StemCell Technologies, Vancouver, Canada) at a concentration of 1000 cells/ml. Single cell suspensions of colonies were serially replated at the same concentration for upto 6 weeks or until the exhaustion of cell growth.
Immunostaining and confocal laser scanning fluorescence microscopy
For intracellular localization studies, the human osteosarcoma cell line U2-OS was grown on coverslips in six-well plates and transiently transfected with pcDNA3-FLAG-AF10, pcDNA3-FLAG-CALM-AF10 or pcDNA3-FLAG-CALM (400-648) þ AF10 (677-758) plasmids using 1 mg plasmid DNA and 1.5 mg polyethyleneimine (Sigma, St Louis, MO, USA). After 24 h, cells were fixed with phosphate-buffered saline 2% paraformaldehyde for 10 min, permeabilized with phosphate-buffered saline 0.1% Triton X for 10 min and blocked with phosphate-buffered saline 10% fetal calf serum for 1 h. Coverslips were incubated overnight with monoclonal mouse FLAG antibodies (Sigma). Following extensive washing with phosphate-buffered saline, Alexa555-conjugated secondary antibodies (Invitrogen, Carlsbad, CA, USA) were added for 1 h. After further washing steps, cells were stained with 4 0 ,6 0 -diamidine-2 0 -phenylindole dihydrochloride (Hoechst, Frankfurt, Germany) and mounted using Cytomation medium (DAKO, Glostrup, Denmark). Finally, immunostained species were analyzed in a confocal fluorescence laser scanning system (TCS-SP2 scanning system and DM IRB inverted microscope; Leica, Solms, Germany).
Western blotting
Total protein was extracted from GFP þ E86 cells to assess the sizes and amounts of CALM-AF10 and CALM (400-648) þ AF10 (677-758) proteins via western blotting, as described before. 18 The membranes were incubated overnight with goat polyclonal anti-CALM antibodies A-2 and C-18 (Santa Cruz Biotechnologies Inc., Santa Cruz, CA, USA) used at a concentration of 200 ng/ml. A horseradish peroxidase conjugated donkey antigoat antibody (100 ng/ml) was used as secondary antibody.
Gene expression profiling and microarray analysis
Mouse BM cells were transduced with CALM-AF10, CALM (400-648) þ AF10 (677-758), CALM-AF10 DOM-LZ and empty vector (MIG). Three days post-transduction, GFP-expressing cells were sorted by fluorescence activated cell sorting and total RNA (including both long and short RNA fractions) was extracted using Qiagen miRNeasy Mini Kit (Hilden, Germany).
For each construct, three biological replicates were produced. Microarray analysis was performed using Affymetrix GeneChip Mouse Gene 1.0 ST and GeneChip miRNA arrays. For the GeneChip Mouse Gene 1.0 ST Array, analyses were performed using 200 ng total RNA as starting material and 5.5 mg ssDNA per hybridization (GeneChip Fluidics Station 450; Affymetrix, Santa Clara, CA, USA). The total RNAs were amplified and labeled following the whole transcript sense target labeling assay (http://www.affymetrix.com). Labeled ssDNA was hybridized to Mouse Gene 1.0 ST Affymetrix GeneChip arrays (Affymetrix). The chips were scanned with an Affymetrix GeneChip Scanner 3000 and subsequent images analyzed using Affymetrix Expression Console Software (Affymetrix). For the GeneChip miRNA Array, 1 mg of total RNA was labeled using the FlashTag Biotin HSR labeling Kit (Genisphere, Hatfield, PA, USA). In all, 21.5 ml biotin-labeled sample were hybridized to GeneChip miRNA Arrays at 48 1C and 60 r.p.m. for 16 h. After washing Wash at a Fluidics Station 450 using fluidics script FS450_0003 arrays were scanned with an Affymetrix GeneChip Scanner 3000. Raw data were background corrected and quantile normalized using the miRNAQCTool from Affymetrix with default parameters recommended by Affymetrix.
A transcriptome analyses was performed using BRB-ArrayTools developed by Dr Richard Simon and BRB-ArrayTools Development Team (http://linus.nci.nih.gov/BRB-ArrayTools.html). Raw feature data were normalized and log 2 intensity expression summary values for each probe set were calculated using robust multiarray average 22 using Affymetrix Expression Console Software (Affymetrix). For class comparison, we identified genes/ miRNAs that were differentially expressed among the two classes using a two-sample t-test. Genes were considered statistically significant if their P-value was o0.05 and displayed a fold change between the two groups of at least 1.5-fold.
Our complete mRNA and miRNA array data are accessible at a gene expression omnibus (http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?token ¼ ltmtnyguieagozi&acc ¼ GSE27514).
Results
CALM-AF10 significantly increases the CFU-S frequency of normal BM progenitors
Sequencing of CALM-AF10 transcripts has revealed splicing events, but has shown that the C-terminal part of CALM with its clathrin-binding domain and the OM-LZ domain are present in patients with AML. 12, 20 We confirmed these findings in three patients with CALM-AF10-positive AML, demonstrating that the C-terminal clathrin-binding domain of CALM and the OM-LZ domain of the AF10 part in the CALM-AF10 fusion gene are not spliced out (data not shown). Based on this finding, we gauged the extent of the contribution of these two domains to the leukemogenic activity of the CALM-AF10 fusion gene. The fulllength CALM-AF10 fusion, which was derived from the t(10;11)(p13-14;q14-21) translocation of the U937 cell line, includes the amino acids 1 to 648 of CALM to amino acids 81-1042 of AF10 (Figure 1a) . In order to assess the impact of short-term CALM-AF10 expression on early hematopoietic progenitors in vivo, we employed the day-12 CFUs in spleen (d-12 CFU-S) assay 21 ( Figure 1b ). Upon injection of BM cells expressing the empty MSCV-IRES-GFP (MIG) vector, an average of 3 ± 1.2 d-12 CFU-S colonies could be recovered per 10 5 input cells, whereas sorted CALM-AF10 transduced BM cells generated an average of 81 ± 5 d-12 CFU-S colonies (Figure 1b) . CALM-AF10 expression therefore increases the d-12 CFU-S activity by B27-fold as compared with empty vector (Po0.0001). We then used this assay to test several deletion mutants to identify protein domains that contribute to the aforementioned hematopoietic activity of the CALM-AF10 fusion.
The OM-LZ of AF10 is necessary and sufficient for the enhancement of CFU-S activity by CALM-AF10
We initially focused on the AF10 part of the fusion and constructed several deletion mutants of the AF10 region. Expression of the CALM gene truncated at the breakpoint of CALM-AF10 (designated CALMD3 0 ) or the CALM-AF10 fusion gene with a deleted OM-LZ domain (designated CALM-AF10 DOM-LZ) gave an average of three and four d-12 CFU-S colonies, respectively, per input 10 5 BM cells. These numbers were similar to d-12 CFU-S colonies obtained from empty vector (MIG) transduced cells, indicating that the AF10 portion of CALM-AF10, especially the OM-LZ domain (amino acids 677-758 of AF10) is necessary for the CFU-S enhancement phenotype. BM cells transduced with a construct harboring the CALM gene fused only to the OM-LZ region of AF10 (CALM þ OM-LZ) showed an average of 54 colonies per 10 5 input cells (an 18-fold increase compared with MIG; P ¼ 0.0005). This effect was comparable to the activity of the full-length CALM-AF10 fusion (CALM-AF10 vs CALM þ OM-LZ; P ¼ 0.065) (Figure 2a) .
Fusion of the clathrin-binding domain of CALM to the OM-LZ domain of AF10 enhances CALM-AF10-mediated transformation
Having established the OM-LZ domain of AF10 as the important determinant of the enhancement in d-12 CFU-S, we turned our attention to the CALM part of the fusion. The N-terminal amino acids of CALM have a high homology to AP180, the neuronal homolog of the CALM protein. These residues (amino acids 1-413), which include the ENTH or ANTH (Epsin or AP180 N-terminal homology) domain, have been shown to be insufficient for the targeting of CALM to clathrin-coated pits. The binding of clathrin to CALM was shown to primarily involve the Cterminal residues 414-652 of CALM. We therefore interrogated these N-and C-terminal portions of CALM for their contribution to the oncogenicity of the CALM-AF10 fusion gene. We generated two CALM deletion mutants fused to the AF10 OM-LZ domain. The CALM (aa 1-410) þ OM-LZ fusion generated an average of 37 d-12 CFU-S colonies, which was comparable to the CALM þ OM-LZ construct. Strikingly, expression of the CALM (aa 400-648) þ AF10 (aa 677-758) mutant, henceforth referred to as the CALM-AF10 minimal fusion (MF) or CALM-AF10 (MF) mutant, profoundly augmented the ability of BM cells to form d-12 CFU-S colonies, with an average of 800 colonies per 10 5 input cells (Pvalue of 0.0033 compared with MIG and o0.0001 compared with CALM-AF10) (Figure 2b) .
The dramatic increase in colony numbers by the CALM-AF10 (MF) mutant suggested that this mutant might confer a significant proliferative advantage to hematopoietic progenitors. We tested the effect of CALM-AF10 (MF) expression in 5-fluorouracil-treated BM cells using methylcellulose-based CFC assays. Unlike the fulllength CALM-AF10 fusion, which fails to transform BM progenitors, under defined conditions in vitro (in the presence of medium supplemented with 6 ng/ml IL3, 100 ng/ml stem cell factor, 10 ng/ml IL6), CALM-AF10 (MF) expression led to a rapid immortalization of hematopoietic precursors (Figure 3) . Specifically, CALM-AF10 (MF) showed a significant increase in the number of secondary CFCs (32-fold vs MIG; 15.38-fold vs CALM-AF10). While CALM-AF10-expressing BM cells typically lost their replating potential in the second week of culture, CALM-AF10 (MF)-expressing BM colonies could be serially replated for at least 4 weeks in CFC assays (Figure 3a ) and proliferated extensively in culture for at least 8 weeks in medium supplemented only with 6 ng/ml IL3 (data not shown). Colonies obtained from CALM-AF10 (MF)-expressing progenitors were typically compact and hypercellular and composed predominantly of cells with a blast-like morphology (Figure 3b ).
Induction of AML by the CALM-AF10 (MF) mutant
In order to ascertain that the transformation potential of the CALM-AF10 (MF) mutant would translate into leukemia generation, we injected CALM-AF10 (MF)-expressing 5-fluorouracil-enriched BM progenitors into lethally irradiated mice. CALM-AF10 (MF) expression induced leukemia in the recipients (n ¼ 9), with a median survival of 110 days (mean 116 days). The latencies of disease in these leukemias were not significantly different (P ¼ 0.86) from leukemias initiated by the full-length CALM-AF10 fusion (median survival 138 days, n ¼ 8). Moreover, similar to the CALM-AF10 mice described previously, 18 CALM-AF10 (MF)-induced leukemias showed diffuse infiltration of large cells with blastic chromatin and prominent nucleolus in the spleen, liver, kidney, intestine, lung and lymph nodes. Myeloperoxidase staining showed massive infiltration of the spleen and other organs with myeloblastic cells (Figure 4a ). The disease induced by the CALM-AF10 (MF) mutant could also be transplanted into secondary recipients who died with a median latency of 31 days post-transplantation (n ¼ 8). Analysis of BM cells from leukemic CALM-AF10 (MF) mice demonstrated the presence of Gr-1/Mac1 þ myeloid blasts. Importantly, all the mice analyzed (n ¼ 5) harbored distinct populations of Mac1 þ / B220-, Mac1 þ /B220 þ and Mac1-/B220 þ cells (Figure 4b ), similar to the hierarchically arranged cell populations described for the full-length CALM-AF10 fusion gene. 18 These findings demonstrate the striking similarity in leukemia presentation, disease latency and transplantability between CALM-AF10 and CALM-AF10 (MF)-induced leukemias, despite the lack of larger portions of the fusion gene in the CALM-AF10 (MF) construct.
Enhanced expression and increased nuclear localization of the CALM-AF10 (MF) mutant
In order to assess the localization and relative expression levels of CALM-AF10 and the CALM-AF10 (MF) mutant, we performed immunofluorescence microscopy using FLAG-tagged, fulllength CALM-AF10 or the CALM-AF10 (MF) mutant constructs transfected in U2-OS cells and used wild-type AF10 as a control. As it has been demonstrated previously, 23 AF10 was predominantly nuclear, whereas CALM-AF10 could be detected in a punctuate pattern in the cytoplasm. Moreover, in contrast to the speckled appearance of CALM-AF10, the CALM-AF10 (MF) protein was rather homogeneously distributed throughout the cytoplasm, with some cells showing an increased level of CALM-AF10 (MF) protein expression in the nucleus (Figure 5a ). Protein expression of the CALM-AF10 (MF) was also confirmed by western blotting (Figure 5b ).
Analysis of global gene expression changes induced by the CALM-AF10 mutants
Our results demonstrated that the CALM-AF10 (MF) mutant can profoundly enhance the proliferative capability of BM Tables S1 and S2, respectively) . Most notably, a number of genes known to be highly expressed in CALM-AF10 leukemias, especially genes of the Hoxa cluster, were significantly upregulated in the CALM-AF10 (MF)-expressing cells as compared with BM cells expressing the full-length CALM-AF10. Figure 6 depicts the differential expression of the Hoxa cluster genes (coding and non-coding) among CALM-AF10, CALM-AF10 (MF) or CALM-AF10 DOM-LZ and empty MIG vector. Interestingly, the Hox cluster embedded microRNA, miR-196b, which has been shown to be upregulated in the human CALM-AF10 T-cell acute lymphoblastic leukemia, 24 was also highly upregulated in CALM-AF10 (MF)-expressing cells ( Figure 6 ). Supplementary Tables S3 and S4 list the differentially expressed mRNAs and miRNAs between CALM-AF10 and CALM-AF10 DOM-LZ, respectively.
Discussion
Breakpoint heterogeneity in chromosomal translocations can be instructive for the identification of domains that are crucial for the transformation potential of oncogenes generated by those fusions. The C-terminal portion of AF10 is retained in all reported CALM-AF10 and MLL-AF10 fusions. 1, 20, 25 This C-terminal region includes the OM-LZ domain and a glutaminerich (Q-rich) domain that are both highly conserved. The OM-LZ domain of AF10 has been shown to interact with a number of important proteins such as the Swi/Snf interacting protein Gas41, 14 the lineage determining transcription factor Ikaros 23 and the histone methyltransferase Dot1l. 13 The OM-LZ domain was shown to be critical for the in vitro transformation capability of the MLL-AF10 fusion gene. 15 Okada et al. 16 demonstrated that the OM-LZ region of AF10 is important for the interaction of CALM-AF10 with Dot1l and that the deletion of this region reduces the proliferative capacity of CALM-AF10 transduced BM cells. We now demonstrate that the OM-LZ domain of AF10 is both necessary for the expansion of early hematopoietic progenitors and also sufficient for in vivo leukemic transformation by the CALM-AF10 fusion gene.
Under conditions routinely used to assay the in vitro myeloid transformation activity of oncogenes, the CALM-AF10 fusion gene failed to transform BM cells in vitro. This is in contrast to its strong leukemogenic effect in vivo. 18, 19 However, expression of the CALM-AF10 (MF) mutant rapidly immortalized BM progenitors in vitro and dramatically increased the recovery or d-12 CFU-S progenitors. It could be that transformation by the full-length CALM-AF10 protein is dependent on collaboration with in vivo niche signaling such as certain growth factors or cellular interactions absent under the aforementioned myeloid in vitro culture conditions, whereas transformation driven by CALM-AF10 (MF) is independent of these factors. In this regard, it is pertinent to observe that CALM-AF10 transduced BM cells can proliferate extensively in media supplemented with fetal thymic organ culture and IL3, 16 but not under more defined cytokine supplemented conditions (unpublished observations), supporting the hypothesis that additional, hitherto unknown growth factors are required for transformation by the full-length CALM-AF10 fusion. Alternatively, it is possible that the in vitro transformation potential of CALM-AF10 (MF) is caused by a greater abundance in the nucleus as compared with the full-length CALM-AF10 protein.
We and others have observed that CALM-AF10 disrupts the physiological activity of the AF10-DOT1L complex, resulting in global H3K79 hypomethylation and HoxA-locus-specific hypermethylation although the exact molecular mechanisms of these epigenetic abnormalities remain obscure. Disruption of the H3K79 methyltransferase activity of the AF10-DOT1L complex is believed, inter alia, to lead to the aberrant overexpression of the HOXA cluster genes typically observed in the CALM-AF10 leukemias. These Hoxa cluster genes (including the microRNA miR-196b) were significantly upregulated after short-term expression of the CALM-AF10 (MF) protein, but to a much lesser extent in the full-length CALM-AF10 transduced BM. These results suggest that the CALM-AF10 (MF) protein might more rapidly and efficiently disrupt the AF10-DOT1L complex, leading to the observed in vitro transformation phenotype.
Lastly, it is possible that the CALM-AF10 (MF) mutant is more efficient at in vitro transformation because the N-terminus (aa 1-410) of the CALM protein, which is not present in the MF, normally impairs the in vitro transformation capability of the full-length CALM-AF10 fusion. Interestingly, the expression of the MF mutant did not alter the latency or phenotype of the disease in the BM transplant setting, suggesting that the lack of pronounced transformation in vitro by the full-length CALM-AF10 protein is compensated by microenvironmental factors in vivo. Although several prior studies on CALM-AF10 have focused on the role of AF10, the potential contribution of the different CALM domains remains to be elucidated. The CALM protein, which is involved in clathrin-mediated endocytosis, has several defined domains. The N-terminal region of CALM (aa 1-300) is highly homologous to the N-terminal region of Epsin and AP180, important components of the endocytic machinery. 26 This domain, which has been termed the ENTH/ANTH domain, binds inositol phospholipids and contributes to the formation of clathrin coats on cell membranes. 27, 28 A large part of this domain is excluded from the MLL-CALM fusion observed in a case of infant AML. 29 Our studies show that the exclusion of the N-terminal amino acids of CALM (which include the E/ANTH domain) from the CALM-AF10 fusion enhances the clonogenic capability of the fusion protein in short-term assays. Furthermore, the presence of the C-terminal amino acids 414-648 of CALM is sufficient to induce leukemia that recapitulates several features of full-length CALM-AF10-induced disease. The C-terminal amino acids (414-648) of CALM have been shown to bind clathrin. 26 A separate study demonstrated that these amino acids possess transcriptional activation potential when fused to a heterologous DNA-binding motif in yeast. 30 Interestingly, since the CALM-AF10 (MF) mutant showed enhanced in vitro transformation potential, several plausible contributions of the C-terminal amino acids of CALM could be hypothesized. Either C-terminal CALM-mediated disruption of endocytosis may interfere with cytokine receptor internalization, or alternatively C-terminal CALM domains may transactivate genes at loci targeted by the Af10-Dotll complex. Our results that the OM-LZ domain of AF10 (aa 677-758) is necessary and sufficient for in vivo leukemia initiation and phenocopies the full-length CALM-AF10 fusion strongly underline the importance of targeting the oncogenic activity of this domain in CALM-AF10 leukemias. Aberrant recruitment of the H3K79 methyltransferase DOT1L by the oncogenic AF10 fusions has been proposed as a major mechanism of leukemogenesis of AF10-rearranged leukemias. This is based on the observation that the DOT1L protein binds to the AF10 OM-LZ domain and that genes of the HoxA gene cluster show H3K79 hypermethylation in CALM-AF10 and MLL-AF10 leukemia cells. 13, 16 Exciting new findings have shown that AF10 is crucial for catalyzing Dot1l-mediated H3K79 methylation, since RNAi-mediated suppression of AF10 leads to a significant reduction in this chromatin modification. 17, 31 The importance of this process is highlighted by the fact that Dot1l-mediated hypermethylation of H3K79 at the HoxA gene cluster could be a critical leukemogenic mechanism in non-AF10 leukemias as well. 32 However, the changes in H3K79 methylation patterns caused by AF10 containing fusion genes are more complicated. We have previously reported a genome-wide hypomethylation of H3K79 in MLL-AF10 and CALM-AF10-expressing leukemias. This genome-wide hypomethylation at H3K79 could be linked to an increase in chromosomal instability. 17 Eight differentially expressed miRNAs were found between the full-length CALM-AF10 and CALM-AF10(DOM-LZ) transduced BM cells. Of note is the downregulation of the pro-apoptotic and anti-proliferative miR-128 in CALM-AF10 compared with CALM-AF10(DOM-LZ). 33, 34 There are 28 mRNAs significantly differentially expressed between CALM-AF10 and CALM-AF10(DOM-LZ) samples. Of these 28 differentially expressed mRNAs, none corresponded to the Hoxa cluster, indicating that this genomic region is not overtly activated in the 3 days post-transduction of the full-length CALM-AF10 BM, in vitro. However, the Hedgehog pathway gene Smo, a homolog of the Drosophila smoothened gene, 35 was upregulated upon full-length CALM-AF10 expression compared with CALM-AF10(DOM-LZ), suggesting that it may have a role in CALM-AF10-mediated transformation. The Hedgehog pathway has been shown to be activated in chronic myeloid leukemia and the loss of the Smo gene was shown to impair chronic myeloid leukemic stem cells. However, it remains to be seen if this pathway is also activated in CALM-AF10 leukemias. Comparison between the full-length CALM-AF10 and CALM-AF10 (MF) transduced BM cells showed that interestingly, in contrast to the full-length CALM-AF10 protein, short-term expression of the CALM-AF10 (MF) mutant significantly upregulated genes of the Hoxa cluster (including miR-196b). Taken together, these results indicate that the CALM-AF10 (MF) mutant is more efficient in activating some of the CALM-AF10-specific leukemogenic programs but lacks the full capacity to induce a more aggressive leukemia in vivo compared with the full-length CALM-AF10. Since most leukemic fusion products are poor targets for pharmacologic inhibition, biochemical changes brought about by these fusions offer promising targets for rational drug design. Even as murine models of CALM-AF10 leukemia recapitulate aspects of their corresponding human malignancies, mechanistic or therapeutic studies on these leukemias could be hampered by the prolonged latency of leukemia initiation in the CALM-AF10 retroviral BM transplantation model 18 and incomplete disease penetrance in the CALM-AF10 transgenic model. 19 In this study, we have demonstrated that the d-12 CFU-S assay can be used as a relatively rapid in vivo assay for CALM-AF10 activity. Using this method, we screened for domains essential for CALM-AF10 function and identified a potent leukemogenic mutant of CALM-AF10, which can immortalize BM progenitors in vitro, and phenocopy leukemia generated by the full-length CALM-AF10 fusion in vivo. The CALM-AF10 (MF) mutant, therefore, lends itself very well to expeditious assessment of transformation in the CALM-AF10 leukemias from mechanistic as well as therapeutic perspectives.
Conflict of interest
The authors declare no conflict of interest.
